“DoxyPEP”, a post-exposure prophylaxis medication to prevent sexually transmitted infections, performed poorly in a new study.
The study looks at young women in Kenya using doxycycline as an antibiotic blocker to many potential STIs including HIV.
In theory, post-exposure prophylaxis provides an alternative to condoms. Pills taken up to 72 hours after intercourse have been shown in previous studies to work for gay and bi men, and trans women. But there has been a comparative lack of research on how effective the treatment is for cis women.
However a paper in the New England Journal of Medicine reports on the findings of this trial, noting that a significant factor seems to be the women in the study not always taking the pills when they should.
On a sample of 449 women, there was a slightly lower rate of infections in the group taking PEP than in the control group.
“Among cisgender women, the incidence of STIs was not significantly lower with doxycycline PEP than with standard care. According to hair-sample analysis, the use of doxycycline PEP among those assigned to receive it was low.” the researchers report.
The hair analysis found traces of the PEP medication in only 29% of samples from the women who were supposed to be using it.
